Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20771160 | 0.89 | GABRA5 (0.44) | GABRA5PTGS2KMT2AATMPTGS1 | |
| SCHEMBL2925549 | 0.86 | ALDH1A1 (0.48) | GABRA5PTGS2KMT2AATMPTGS1 | |
| SCHEMBL1776269 | 0.83 | PTGS2 (0.50) | GABRA5PTGS2KMT2AATMPTGS1 | |
| SCHEMBL21834100 | 0.83 | GABRA5 (0.49) | GABRA5PTGS2KMT2AATMPTGS1 | |
| SCHEMBL286512 | 0.83 | GABRA5 (0.49) | GABRA5PTGS2KMT2AATMPTGS1 | |
| SCHEMBL2928713 | 0.83 | GABRA5 (0.52) | GABRA5GPBAR1 | |
| SCHEMBL22230645 | 0.83 | GABRA5 (0.49) | GABRA5PTGS2KMT2APTGS1 | |
| SCHEMBL107436 | 0.83 | PTGS1 (0.58) | GABRA5PTGS2KMT2APTGS1 | |
| SCHEMBL2961416 | 0.83 | GABRA5 (0.50) | GABRA5KMT2ATHRB | |
| SCHEMBL5772937 | 0.83 | MAPT (0.54) | GABRA5KMT2ATHRBGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675845-B1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIV MARYLAND (US) | 2024-07-17 | — | — | EP | claimed |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-12-15 | — | — | US | claimed |
| US-11459320-B2 | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-10-04 | — | — | US | claimed |
| WO-2019046300-A9 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3675845-A1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | University of Maryland, Baltimore (US) | 2020-07-08 | — | — | EP | claimed |
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-25 | — | — | US | claimed |
| CN-111201016-A | Novel gamma aminobutyric acid type A receptor modulators for mood disorders | 马里兰大学巴尔的摩分校 | 2020-05-26 | — | — | CN | claimed |
| WO-2019046300-A1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-03-07 | — | — | WO | claimed |
| EP-2768827-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-11-23 | — | — | EP | claimed |
| EP-2768827-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-27 | — | — | EP | claimed |
| US-8604062-B2 | Process for the preparation of isoxazolyl-methoxy nicotinic acids | HOFFMAN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | claimed |
| WO-2013057123-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | claimed |
| US-20130102778-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | claimed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2025-07-29 | — | — | US | disclosed |
| WO-2009071477-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | GABRA5 1/4885PTGS2 3620/4885KMT2A 3647/4885 |
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885PTGS2 3790/4885KMT2A 1378/4885 |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | GABRA5, GABRA1, GABRB1 | GABRA5 1/4885PTGS2 2889/4885KMT2A 4329/4885 |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | GABRA5 1/4885PTGS2 1436/4885KMT2A 3099/4885 |
| US-11459320-B2 | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885PTGS2 3790/4885KMT2A 1378/4885 |
| US-20130102778-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS | NAPRT, CHRNA1, CHRM1 | GABRA5 151/4885PTGS2 2191/4885KMT2A 2326/4885 |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885PTGS2 3790/4885KMT2A 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.